Literature DB >> 31806280

The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension.

Roberto Badagliacca1, Silvia Papa2, Hiromi Matsubara3, Irene Marthe Lang4, Roberto Poscia2, Giovanna Manzi2, Carmine Dario Vizza2.   

Abstract

Pulmonary arterial hypertension is an obstructive pulmonary vasculopathy that leads to increased pulmonary vascular resistance, right ventricular overload and failure, and death. Patients' clinical status and prognosis depend mostly on the capability of the right ventricle to adapt to the increased afterload, maintain function, and preserve cardiac output. As a result, reducing the hemodynamic burden of the right ventricle should be a key target of current treatments, along with improvement in WHO functional class, 6-minute walk distance, and rates of hospitalization. However, physicians still find it challenging to integrate the evaluation of right ventricular function into widely accepted clinical parameters in order to stratify patients more accurately. This limitation is very relevant, since higher-risk patients are more likely to benefit from a more aggressive therapeutic approach. We analyzed the hemodynamic burden in pulmonary arterial hypertension, the importance of echocardiographic evaluation of the right ventricle, the impact of current treatments on hemodynamic parameters, and the identification of patients who are more likely to benefit from a more aggressive therapeutic approach.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Echocardiogram; Hemodynamic; Pulmonary arterial hypertension; Pulmonary vascular resistance; Right ventricle

Mesh:

Year:  2019        PMID: 31806280     DOI: 10.1016/j.ijcard.2019.10.043

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension.

Authors:  Kadriye Memic Sancar; Mustafa Yildiz; Serkan Kahraman; Begum Uygur; Umit Bulut; Meltem Tekin; Arda Guler; Nail Guven Serbest; Seda Tukenmez Karakurt; Banu Sahin Yildiz; Ahmet Yasar Cizgici; Muhammed Bayram; Mehmet Erturk
Journal:  Herz       Date:  2022-09-23       Impact factor: 1.740

2.  Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury.

Authors:  Ran Miao; Juanni Gong; Xiaojuan Guo; Dichen Guo; Xinyuan Zhang; Huimin Hu; Jiuchang Zhong; Yuanhua Yang; Yidan Li
Journal:  BMC Pulm Med       Date:  2022-04-29       Impact factor: 3.320

3.  Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients.

Authors:  Wei-Fang Lan; Yan Deng; Bin Wei; Kai Huang; Ping Dai; Shan-Shan Xie; Dan-Dan Wu
Journal:  Front Cardiovasc Med       Date:  2022-05-03

Review 4.  Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Authors:  Shu-Hao Wu; Yih-Jer Wu
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

Review 5.  The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece.

Authors:  Cristiano Miotti; Silvia Papa; Giovanna Manzi; Gianmarco Scoccia; Federico Luongo; Federica Toto; Claudia Malerba; Nadia Cedrone; Susanna Sciomer; Francesco Ciciarello; Francesco Fedele; Carmine Dario Vizza; Roberto Badagliacca
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

6.  Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?

Authors:  Roberto Badagliacca; Michele D'Alto; Stefano Ghio; Carmine Dario Vizza; Robert Naeije
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

7.  Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension.

Authors:  Giovanna Manzi; Cristiano Miotti; Marco Valerio Mariani; Silvia Papa; Federico Luongo; Gianmarco Scoccia; Beatrice De Lazzari; Claudio De Lazzari; Raymond L Benza; Francesco Fedele; Carmine Dario Vizza; Roberto Badagliacca
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

8.  E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension.

Authors:  Sandeep Sahay; Jiken Bhatt; Sarah Beshay; Ashrith Guha; Duc T Nguyen; Edward A Graviss; Sherif F Nagueh
Journal:  Pulm Circ       Date:  2022-01-12       Impact factor: 2.886

9.  Comment on Topyła-Putowska et al. Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. J. Clin. Med. 2021, 10, 3229.

Authors:  Giovanna Manzi; Carmine Dario Vizza; Roberto Badagliacca
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

10.  Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography.

Authors:  Valentina Mercurio; Hussein J Hassan; Mario Naranjo; Alessandra Cuomo; Jeremy A Mazurek; Paul R Forfia; Aparna Balasubramanian; Catherine E Simpson; Rachel L Damico; Todd M Kolb; Stephen C Mathai; Steven Hsu; Monica Mukherjee; Paul M Hassoun
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.